Video

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE

Name: Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE
Uploaded: T00:00:00+00:00
Description: Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin.

Overview

Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin.

Published

Created by

Related Presenters

Pablo Mora, FACE, MD

Dallas Diabetes Research Center at Medical City Dallas (Texas)Adjunct Associate Professor University of Texas Southwestern Medical Center at Dallas (Texas)